Share

    


Home / Search Results

Search Results

You searched for:

ACCC in partnership with HealthTree Foundation for Acute Myeloid Leukemia, has launched an education program to explore the current barriers in care coordination and therapy options for patients with AML who are not eligible for transplant.
In this episode, CANCER BUZZ speaks with Farrukh T. Awan, MD, MS, professor of Internal Medicine and director of Lymphoid Malignancies at the Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, about their approach to addressing regional barriers to improve care for patients with chronic lymphocytic leukemia.
Personalizing care goals to account for a patient’s values, preferences, or circumstances can make a significant difference in shared decision-making and treatment planning. In this episode, CANCER BUZZ speaks with Melissa Kah Poh Loh, MBBCh, BAO, assistant professor of Geriatric Hematology and Oncology at the University of Rochester Medical Center’s Wilmot Cancer Institute about strategies …
While there are many factors why patients with acute myeloid leukemia are ineligible for allogeneic stem cell transplant, such as age, financial hurdles, or other comorbidities, these factors are often compounded by social determinants of health, which can act as a significant barrier to consolidation therapy and long-term remission for these patients. In this episode, CANCER BUZZ speaks with Keri …
Key findings from three case studies highlight the challenges and triumphs in treating chronic lymphocytic leukemia with oral oncolytics.
Tune-in as Dr. Hobbs discusses symptom scoring, risk stratification, and effective practices in building a strong myelofibrosis program.
With the treatment of chronic lymphocytic leukemia (CLL) shifting substantially in the last five years, learn how ACCC is supporting oncology professionals in integrating oral oncolytics in CLL practice.
With data already demonstrating the role of MRD for CLL response assessment and prognosis, cancer programs should prepare themselves for implementation of MRD testing for appropriate patients.
Testing for measurable residual disease can shape treatment choices and patient management to achieve better outcomes, and the need persists for members of the multidisciplinary cancer care team to better understand the purpose, use, and significance of this testing in all cancer treatment settings.